Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Sprint Bioscience AB (publ) is a pharmaceutical company focused on developing therapies for cancer and metabolic disorders. Its operations span internationally, with a presence in Sweden, across Europe, the United States, and Asia. The firm is currently advancing key drug candidates, including VPS34, which is being developed to treat various forms of cancer, and PETRA01, another prospective cancer treatment. Additionally, the company dedicates research efforts to understanding and treating conditions such as tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was established in 2009 and maintains its headquarters in Huddinge, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, under
Target Price
The average target price of SPRINT.ST is 4.8 and suggests 27% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in